Showing 1 - 2 results of 2 for search 'Daniel A. Morgenstern', query time: 0.01s Refine Results
  1. 1
    DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibition

    DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibition by Madeline N. Hayes, Sarah Cohen-Gogo, Lynn Kee, Xueting Xiong, Alex Weiss, Mehdi Layeghifard, Yagnesh Ladumor, Ivette Valencia-Sama, Anisha Rajaselvam, David R. Kaplan, Anita Villani, Adam Shlien, Daniel A. Morgenstern, Meredith S. Irwin

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial

    The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial by Jaume Mora, Godfrey C. F. Chan, Daniel A. Morgenstern, Loredana Amoroso, Karsten Nysom, Jörg Faber, Arthur Wingerter, Melissa K. Bear, Alba Rubio-San-Simon, Blanca Martínez de Las Heras, Karen Tornøe, Maria Düring, Brian H. Kushner

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: